There's nothing wrong with owning index funds, but growth stocks by definition outpace the revenue or profit of a typical stock, which likely results in greater gains than index funds can produce.

Vertex Pharmaceuticals (NASDAQ: VRTX) and Novo Nordisk (NYSE: NVO) fit the definition of a growth stock. These two pharmaceutical companies have products that have helped them outpace the S 500's total return over the past five years, and they certainly have the potential to continue doing so.

Vertex, known for its range of cystic fibrosis (CF) therapies, has increased revenue by 193% over the past five years -- and the company's growth trend could just be getting started.

Continue reading

Source Fool.com